Tim Watkins
Known title: CMO & Head of DevelopmentCIK: 0002065965
Associated companies
Transaction History
| CTNM | ▲ Buy | Option Exercise | 10,833 | $49K | 6/30/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 10,833 | $174K | 6/30/2026 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 3,611 | $16K | 3/2/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 3,611 | $54K | 3/2/2026 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 3,611 | $16K | 1/28/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 2,800 | $39K | 1/28/2026 | View on chart |
| CTNM | ▼ Sell | Open Market | 811 | $12K | 1/28/2026 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 3,611 | $16K | 12/29/2025 | View on chart |
| CTNM | ▼ Sell | Open Market | 3,611 | $44K | 12/29/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
CTNM Depressed After Phase 2 Miss
Contineum Therapeutics recently announced that its depression drug, developed with Johnson & Johnson, failed to meet its primary goal in a Phase 2 trial. This clinical setback is a significant event for the company, as it raises questions about the future development timeline and potential commercialization of the asset. The stock is currently trading near its 52-week low, reflecting the market's reaction to this negative data.
CTNM Depressed After Phase 2 Miss. Contineum Therapeutics recently announced that its depression drug, developed with Johnson & Johnson, failed to meet its primary goal in a Phase 2 trial. This clinical setback is a significant event for the company, as it raises questions about the future development timeline and potential commercialization of the asset. The stock is currently trading near its 52-week low, reflecting the market's reaction to this negative data.